Greg Adams, PhD

Greg Adams is SVP, Research. He leads the company’s discovery programs and supports its biology and translational studies.

Greg is an immunologist with over 35 years of experience developing antibody-based agents for the treatment and detection of cancer. He was previously the Chief Scientific Officer of Elucida Oncology, where he led the scientific efforts from discovery through early clinical development for cancer-targeted ultra-small nanoparticle drug conjugates; Chief Scientific Officer at Sesen Bio/Eleven Biotherapeutics, developing immunotoxins for the treatment of non-muscle invasive bladder cancer; and Chief Development Officer at Viventia Bio. Before moving to biotech, Greg was on the faculty of Fox Chase Cancer Center (FCCC), an NCI-designated comprehensive cancer center in Philadelphia, PA. While there, he developed monoclonal and bispecific antibodies and antibody-drug conjugates for the treatment of breast, ovarian and renal cancers, was the Director of Biological Research and Therapeutics and co-led the Developmental Therapeutics Program. 

He serves on the Editorial Board of Cancer Immunology Research and has served on the Scientific Advisory Boards of numerous biotechnology companies including Mersana, Endo Pharmaceuticals, Symphogen, Avipep, Viventia Bio, Xerion, Fabrus, Integral Molecular and YM Biosciences.

Greg holds a Ph.D. in Immunology from the University of California at Davis and completed a post-doctoral fellowship at FCCC.